Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00004361 |
Recruitment Status
:
Completed
First Posted
: October 19, 1999
Last Update Posted
: June 24, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
OBJECTIVES: I. Identify latent hypoparathyroidism in normocalcemic adult survivors with repaired conotruncal cardiac defects, by evaluating parathyroid gland secretory function after induced hypocalcemia.
II. Determine the relationship of parathyroid hormone secretion to microdeletions in the same region of chromosome 22q11 as found in patients with DiGeorge anomaly.
Condition or disease | Intervention/treatment |
---|---|
Hypoparathyroidism Tetralogy of Fallot Pulmonary Valve Stenosis Conotruncal Cardiac Defects Heart Defects, Congenital Pulmonary Atresia | Drug: calcium gluconate Drug: sodium citrate |
PROTOCOL OUTLINE:
Patients are given sodium citrate over a 2 hour infusion on day 1. Blood is drawn at times -30, -15, 0, and every 10 minutes thereafter during the infusion. On day 2, patients are given calcium gluconate over a 2 hour infusion. Blood is drawn at times -30, -15, 0, and every 10 minutes thereafter during the infusion.
Study Type : | Observational |
Enrollment : | 150 participants |
Primary Purpose: | Screening |
Study Start Date : | July 1995 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
- Diagnostically shown repaired or palliated conotruncal cardiac defects, including tetralogy of Fallot with pulmonary stenosis or pulmonary atresia, truncus arteriosus, or interrupted aortic arch type B

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004361
Study Chair: | Craig B. Langman | Ann & Robert H Lurie Children's Hospital of Chicago |
ClinicalTrials.gov Identifier: | NCT00004361 History of Changes |
Other Study ID Numbers: |
199/11936 NU-553 |
First Posted: | October 19, 1999 Key Record Dates |
Last Update Posted: | June 24, 2005 |
Last Verified: | January 2001 |
Keywords provided by Office of Rare Diseases (ORD):
DiGeorge syndrome cardiovascular and respiratory diseases conotruncal cardiac defects endocrine disorders genetic diseases and dysmorphic syndromes |
hypoparathyroidism pulmonary valve stenosis rare disease tetralogy of Fallot |
Additional relevant MeSH terms:
Hypoparathyroidism Congenital Abnormalities Heart Defects, Congenital Tetralogy of Fallot Pulmonary Atresia Pulmonary Valve Stenosis Parathyroid Diseases Endocrine System Diseases Cardiovascular Abnormalities Cardiovascular Diseases Heart Diseases Vascular Malformations |
Heart Valve Diseases Ventricular Outflow Obstruction Calcium, Dietary Citric Acid Bone Density Conservation Agents Physiological Effects of Drugs Anticoagulants Calcium Chelating Agents Chelating Agents Sequestering Agents Molecular Mechanisms of Pharmacological Action |